// App-Quantinova.ai

: Baseline PET-Derived Metabolic Tumor Volume Metrics Did Not Predict Outcomes in Follicular Lymphoma Patients Treated with First-Line Immunochemotherapy and Antibody Maintenance in the Phase III GALLIUM Study

Researchers

Presenter

  • Sally F Barrington

Principal Investigators

  • Judith Trotman

  • Deniz Sahin

  • David Belada

  • Andrew Davies

  • Robert MacEwan

  • Carolyn Owen

  • Vclav Ptcnk

  • Andrs Rosta

  • Wolfgang Hiddemann

  • Robert Marcus

  • Tina Nielsen

  • Federico Mattiello

  • Harald Zeuner

  • Michel Meignan

Medical Centers

  • King's College London and Guy's and St Thomas' PET Centre, King's College London, London, United Kingdom

  • Concord Repatriation General Hospital, University of Sydney, Sydney, Australia

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • University Hospital and Faculty of Medicine, Hradec Kralove, Czech Republic

  • Cancer Sciences, University of Southampton, Southampton, United Kingdom

  • University of Alberta, Cross Cancer Institute, Edmonton, AB, Canada

  • Foothills Medical Center and Tom Baker Cancer Centre, Calgary, Canada

  • First Faculty of Medicine, Charles University, Prague, Czech Republic

  • National Institute of Oncology, Budapest, Hungary

  • Department of Neurosurgery, Ludwig-Maximilians University Munich, Munich, Germany

  • Kings College London, London, United Kingdom

  • Hôpital Henri Mondor and Université Paris-Est Créteil, Paris, France

Locations

  • United Kingdom

  • Australia

  • Switzerland

  • Czech Republic

  • Canada

  • Hungary

  • Germany

  • France

Companies

  • F. Hoffmann-La Roche

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Follicular lymphoma

Biomarkers

  • DNA Damage Inducible Transcript 3

  • Total lesion glycolysis

Drug/Treatment

  • Bendamustine

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT01332968

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved